DexCom, Inc. (NASDAQ:DXCM) SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $122.20, for a total value of $48,880.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Patrick Michael Murphy also recently made the following trade(s):
- On Monday, September 10th, Patrick Michael Murphy sold 2,372 shares of DexCom stock. The shares were sold at an average price of $143.69, for a total value of $340,832.68.
- On Friday, August 10th, Patrick Michael Murphy sold 12,500 shares of DexCom stock. The shares were sold at an average price of $124.18, for a total value of $1,552,250.00.
DXCM stock traded up $4.67 during trading on Friday, reaching $127.07. The stock had a trading volume of 74,456 shares, compared to its average volume of 1,152,085. DexCom, Inc. has a 52 week low of $43.74 and a 52 week high of $148.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. The company has a market cap of $12.64 billion, a price-to-earnings ratio of -214.42 and a beta of 0.47.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.08. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The company had revenue of $242.50 million for the quarter, compared to the consensus estimate of $205.81 million. During the same quarter in the prior year, the company earned ($0.16) earnings per share. DexCom’s revenue was up 42.1% on a year-over-year basis. Equities analysts predict that DexCom, Inc. will post -0.47 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the business. Cerebellum GP LLC bought a new position in DexCom in the second quarter valued at about $171,000. Cibc Bank USA bought a new position in DexCom in the third quarter valued at about $268,000. Clinton Group Inc. bought a new position in DexCom in the second quarter valued at about $201,000. Bank Pictet & Cie Asia Ltd. bought a new position in DexCom in the second quarter valued at about $218,000. Finally, Accredited Investors Inc. bought a new position in DexCom in the second quarter valued at about $225,000.
DXCM has been the topic of a number of research analyst reports. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Raymond James raised DexCom from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. BMO Capital Markets upped their price target on DexCom to $112.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. Finally, Stephens upped their price target on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, August 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. DexCom presently has a consensus rating of “Buy” and an average target price of $123.13.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Asset Allocation
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.